-
Product Insights
Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Drugs In Development, 2023’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyskinesia - Drugs In Development, 2023’, provides an overview of the Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AUR-105 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUR-105 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AUR-105 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details:AUR-105 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NeuP-12
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NeuP-12 Drug Details NeuP-12 is under development for the treatment of neuropathic pain and ...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – piromelatine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry piromelatine Drug Details Piromelatine (Neu-P11) is under development for the treatment of ocular hypertension,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – melatonin ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry melatonin ER Drug Details Melatonin (Circadin, Slenyto) belongs to the class of organic compounds...
-
Product Insights
Insomnia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorders, stress, and shift working. The Insomnia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and...
-
Product Insights
Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glaucoma signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision, and reddening of the eye. The Glaucoma pipeline drugs market research report provides an analysis of the Glaucoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...